{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:14:29Z","timestamp":1740107669586,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Science and Technology Bureau of Yibin City","award":["No. 2015 SF 027"],"award-info":[{"award-number":["No. 2015 SF 027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00705-020-04713-4","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T09:03:40Z","timestamp":1593421420000},"page":"2013-2020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China"],"prefix":"10.1007","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-5514","authenticated-orcid":false,"given":"Bin","family":"Nie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongcan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaijiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunguang","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"1","key":"4713_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77\u201387","journal-title":"Hepatology"},{"key":"4713_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/liv.13668","volume":"38","author":"V Calvaruso","year":"2018","unstructured":"Calvaruso V, Petta S, Crax\u00ec A (2018) Is global elimination of HCV realistic? Liver Int 38:40\u201346","journal-title":"Liver Int"},{"issue":"suppl2","key":"4713_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1471-2334-12-S2-S2","volume":"12","author":"S Zaltron","year":"2012","unstructured":"Zaltron S, Spinetti A, Biasi L et al (2012) Chronic HCV infections: epidemiological and clinical relevance. BMC Infect Dis 12(suppl2):S2","journal-title":"BMC Infect Dis"},{"key":"4713_CR4","doi-asserted-by":"crossref","unstructured":"Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10(5):659\u2013672","DOI":"10.1586\/erv.11.55"},{"issue":"7","key":"4713_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.45","volume":"1","author":"R Geller","year":"2016","unstructured":"Geller R, Estada \u00da, Peris JB, Andreu I, Bou JV, Garijo R, Sanju\u00e1n R (2016) Highly heterogeneous mutation rates in the hepatitis C virus genome. Nat Microbiol 1(7):1\u20137","journal-title":"Nat Microbiol"},{"key":"4713_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jmv.20307","volume":"75","author":"L Lu","year":"2005","unstructured":"Lu L, Nakano T, He Y et al (2005) Hepatits C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 75:538\u2013549","journal-title":"J Med Virol"},{"issue":"4","key":"4713_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3892\/ijmm.2015.2321","volume":"36","author":"B Nie","year":"2015","unstructured":"Nie B, Zhang G, Guo Y et al (2015) Phylogenetic analysis of HCV subgenotypes in patients from Sichuan province in China based on the NS5B region. Int J Mol Med 36(4):1028\u20131034","journal-title":"Int J Mol Med"},{"key":"4713_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3892\/ijmm.2012.1209","volume":"31","author":"Q Cai","year":"2013","unstructured":"Cai Q, Zhao Z, Liu Y et al (2013) Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay. Int J Mol Med 31:347\u2013352","journal-title":"Int J Mol Med"},{"key":"4713_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3350\/cmh.2016.22.1.168","volume":"22","author":"JW Choi","year":"2016","unstructured":"Choi JW, Lee JS, Paik WH et al (2016) Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol 22:168\u2013171","journal-title":"Clin Mol Hepatol"},{"key":"4713_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2893.2008.01012.x","volume":"16","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem S, Berg T, Moeller B et al (2009) Expert opinion on the treatment of patients with chronic hepatits C. J Viral Hepat 16:75\u201390","journal-title":"J Viral Hepat"},{"issue":"11","key":"4713_CR11","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.bmcl.2017.01.017","volume":"27","author":"JL Paparin","year":"2017","unstructured":"Paparin JL, Amador A, Badaroux E, Bot S, Caillet C, Convard T et al (2017) Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor. Bioorgan Med Chem Lett 27(11):2634\u20132640","journal-title":"Bioorgan Med Chem Lett"},{"key":"4713_CR12","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/jac\/dkr215","volume":"66","author":"V Soriano","year":"2011","unstructured":"Soriano V, Vispo E, Poveda E et al (2011) Directly acting antivirals against hepatits C virus. J Antimicrob Chemother 66:1673\u20131686","journal-title":"J Antimicrob Chemother"},{"key":"4713_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","volume":"108","author":"E Poveda","year":"2014","unstructured":"Poveda E, Wyles DL, Mena A et al (2014) Update on hepatits C virus resistance to direct-acting antiviral agents. Antiviral Res 108:181\u2013191","journal-title":"Antiviral Res"},{"key":"4713_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.dld.2010.09.007","volume":"43","author":"R Bruno","year":"2011","unstructured":"Bruno R, Cima S, Maiocchi L et al (2011) Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C. Dig Liver Dis 43:337\u2013344","journal-title":"Dig Liver Dis"},{"issue":"8","key":"4713_CR15","doi-asserted-by":"publisher","first-page":"e0159924","DOI":"10.1371\/journal.pone.0159924","volume":"11","author":"DA Kliemann","year":"2016","unstructured":"Kliemann DA, Tovo CV, Da Veiga ABG, Machado AL, West J (2016) Genetic barrier to direct acting antivirals in HCV sequences deposited in the European databank. PloS One 11(8):e0159924","journal-title":"PloS One"},{"key":"4713_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/jvh.12051","volume":"20","author":"R Alves","year":"2013","unstructured":"Alves R, Queiroz AT, Pessoa MG et al (2013) The presence of resistance mutations to protease and polymerase inhibitors in hepatits C virus sequences from the Los Alamos databank. J Viral Hepat 20:414\u2013421","journal-title":"J Viral Hepat"},{"key":"4713_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/01.qai.0000209899.05126.e4","volume":"41","author":"DA Van de Vijver","year":"2006","unstructured":"Van de Vijver DA, Wensing AM, Angarano G et al (2006) The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41:352\u2013360","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4713_CR18","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1053\/j.gastro.2007.03.116","volume":"132","author":"JM Pawlotsky","year":"2007","unstructured":"Pawlotsky JM, Chevaiez S, McHutchison JG (2007) The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132:1979\u20131998","journal-title":"Gastroenterology"},{"key":"4713_CR19","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/hep.24262","volume":"53","author":"JM Pawlotsky","year":"2011","unstructured":"Pawlotsky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatits C virus. Hepatology 53:1742\u20131751","journal-title":"Hepatology"},{"key":"4713_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","volume":"10","author":"JJ Kiser","year":"2013","unstructured":"Kiser JJ, Burton JR, Everson GT (2013) Drug-drug interactions during antiviral therapy for chronic hepatits C. Nat Rev Gastroenterol Hepatol 10:596\u2013606","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4713_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jhep.2009.03.015","volume":"51","author":"C Cooper","year":"2009","unstructured":"Cooper C, Lawitz EJ, Ghali P et al (2009) Evaluation of VCH-759 monotherapy in hepatits C infection. J Hepatol 51:39\u201346","journal-title":"J Hepatol"},{"issue":"2","key":"4713_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138(2):447\u2013462","journal-title":"Gastroenterology"},{"key":"4713_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4155\/fmc.11.53","volume":"3","author":"ML Barreca","year":"2011","unstructured":"Barreca ML, Iraci N, Manfroni G et al (2011) Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. Future Med Chem 3:1027\u20131055","journal-title":"Future Med Chem"},{"key":"4713_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molcel.2016.01.024","volume":"62","author":"N Pirakitikulr","year":"2016","unstructured":"Pirakitikulr N, Kohlway A, Lindenbach BD et al (2016) The coding region of the HCV genome contains a network of regulatory RNA structures. Mol Cell 62:111\u2013120","journal-title":"Mol Cell"},{"key":"4713_CR25","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/hep.26388","volume":"58","author":"F McPhee","year":"2013","unstructured":"McPhee F, Hernandez D, Yu F et al (2013) Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasivr and asunaprevir. Hepatology 58:902\u2013911","journal-title":"Hepatology"},{"key":"4713_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1128\/AAC.05611-11","volume":"56","author":"PJ Troke","year":"2012","unstructured":"Troke PJ, Lewis M, Simpson P et al (2012) Characterization of resistance to the non-nucleoside NS5B inhibitor filibuvir in hepatitis C virus infected patients. Antimicrob Agents Chemother 56:1331\u20131341","journal-title":"Antimicrob Agents Chemother"},{"key":"4713_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1039\/c3mb70498j","volume":"10","author":"P Jiao","year":"2014","unstructured":"Jiao P, Xue W, Shen Y et al (2014) Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study. Mol Biosyst 10:767\u2013777","journal-title":"Mol Biosyst"},{"key":"4713_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1056\/NEJMc1307641","volume":"369","author":"CS Hsu","year":"2013","unstructured":"Hsu CS (2013) Sofosbuvir for previously untreated chronic hepatits C infection. N Engl J Med 369:678","journal-title":"N Engl J Med"},{"key":"4713_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM (2014) Sofosbuvir: a review of its use in patients with chronic hepatits C. Drugs 74:1127\u20131146","journal-title":"Drugs"},{"issue":"6","key":"4713_CR30","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam AM, Espiritu C, Bansal S, Steuer HMM, Niu C, Zennou V et al (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56(6):3359\u20133368","journal-title":"Antimicrob Agents Chemother"},{"key":"4713_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/infdis\/jit562","volume":"209","author":"X Tong","year":"2014","unstructured":"Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Najera I (2014) In vivo emer-gence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibi-tors mericitabine and sofosbuvir. J Infect Dis 209:668\u2013675","journal-title":"J Infect Dis"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04713-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-020-04713-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-020-04713-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:44:01Z","timestamp":1624927441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-020-04713-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4713"],"URL":"https:\/\/doi.org\/10.1007\/s00705-020-04713-4","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"type":"print","value":"0304-8608"},{"type":"electronic","value":"1432-8798"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"27 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interest pertaining to the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in the present study, which involves human participants, were in strict accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments. Written consent was obtained from all of the subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}